Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272753
Status:
COMPLETED
Last Update Posted:
2011-06-01
First Post:
2006-01-04
Brief Title:
Effect of Budesonide Formoterol Combination in Repeated AMP Provocations
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler BudesonideFormoterol Combination Formoterol Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma Investigating the Supplementary Value of the Budesonide Component Within Symbicort When Tested in a Model of Slow Onset Acute Asthma
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim is to study whether the budesonide component within the budesonide formoterol combination inhaler has additive value in a model of slow onset acute asthma namely three AMP provocation tests performed on one day
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None